PCaVISTAPCaVision and MRI for Prostate Cancer Detection in Biopsy-Naïve and Active Surveillance Men

This study focuses on finding the best way to detect significant prostate cancer by comparing two different imaging methods: PCaVision and MRI. It targets men aged 18 and older who are either newly undergoing testing for prostate cancer or are already under active surveillance after previous tests. The goal is to see if the PCaVision method, which uses advanced ultrasound technology, is just as effective as the MRI method in identifying important cases of prostate cancer that need treatment. This could potentially make diagnosis more accessible and affordable, as MRI can be costly and less available. Participants will undergo both PCaVision ultrasound imaging and MRI scans. If either test finds suspicious areas, targeted biopsies will be performed to examine these areas more closely. Depending on the number of suspicious spots, up to 12 biopsies may be taken in one visit. The study will assess the ability of each imaging method to detect significant prostate cancer, aiming to prove that PCaVision is not less effective than MRI. While the study may involve some minor risks like infection or bleeding from the biopsies, these are considered low. The findings could lead to better diagnostic options for those at risk of prostate cancer, especially in places where MRI is not readily available.